Related Experiment Video
Updated: May 11, 2026
05:04
In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
Published on: February 22, 2022
In vivo TLR9 inhibition attenuates CpG-induced myocardial dysfunction.
O Boehm1, P Markowski, M van der Giet
1Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany.
Mediators of Inflammation
|May 22, 2013
Summary
Toll-like receptor 9 (TLR9) plays a key role in sepsis-induced heart dysfunction. Inhibiting TLR9 with specific compounds like H154-thioate significantly improves survival and cardiac function in a mouse model of sepsis.
Area of Science:
- Immunology
- Cardiovascular Biology
- Microbiology
Background:
- Sepsis can lead to cardiac depression, but the role of toll-like receptor 9 (TLR9) in this process remains unclear.
- TLR9 recognizes bacterial DNA and is implicated in inflammatory responses.
- Understanding TLR9's in vivo role is crucial for developing targeted sepsis therapies.
Purpose of the Study:
- To investigate the role of TLR9 in sepsis-induced cardiac dysfunction in a murine model.
- To evaluate the efficacy of potential TLR9 inhibitors in protecting the cardiovascular system during sepsis.
Main Methods:
- Sepsis was induced in wild-type and TLR9-deficient mice using a TLR9 agonist (1668-thioate).
- TLR9 antagonists (H154-thioate, IRS954-thioate, chloroquine) were administered post-stimulation.
- Survival, cardiac inflammatory mediator expression, and hemodynamic parameters were assessed.
Main Results:
- TLR9 activation in wild-type mice led to sepsis-like symptoms, increased mortality, cardiac inflammation, and heart failure.
- These effects were absent in TLR9-deficient mice, confirming TLR9's central role.
- H154-thioate significantly reduced cardiac inflammation, preserved cardiac function, and improved survival, demonstrating its efficacy as a TLR9 inhibitor.
Conclusions:
- TLR9 is a critical mediator of septic cardiac depression and mortality.
- Inhibition of TLR9, particularly with H154-thioate, offers a promising therapeutic strategy for sepsis-induced cardiovascular complications.